Dearborn Partners’s Bristol-Myers Squibb BMY Stock Holding History

Dearborn Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Buy	4,748 +993	+26%	+$57.9K	0.02%	232
2025 Q4	$203K	Buy	+3,755	New	+$181K	0.01%	259
2025 Q2	–	Sell	-3,755	Closed	-$229K	–	261
2025 Q1	$229K	Hold	3,755	–	–	0.01%	240
2024 Q4	$212K	Buy	+3,755	New	+$210K	0.01%	253
2024 Q2	–	Sell	-6,218	Closed	-$337K	–	258
2024 Q1	$337K	Sell	6,218 -2,056	-25%	-$105K	0.01%	195
2023 Q4	$425K	Sell	8,274 -399	-5%	-$20.9K	0.02%	173
2023 Q3	$503K	Sell	8,673 -252	-3%	-$15.4K	0.02%	153
2023 Q2	$571K	Buy	8,925 +891	+11%	+$59.7K	0.02%	144
2023 Q1	$557K	Sell	8,034 -1,500	-16%	-$106K	0.02%	145
2022 Q4	$686K	Buy	9,534 +1,193	+14%	+$90K	0.03%	131
2022 Q3	$593K	Sell	8,341 -251	-3%	-$18.2K	0.03%	141
2022 Q2	$662K	Buy	8,592 +200	+2%	+$15.2K	0.03%	138
2022 Q1	$613K	Buy	8,392 +308	+4%	+$20.7K	0.02%	154
2021 Q4	$504K	Sell	8,084 -2,507	-24%	-$147K	0.02%	168
2021 Q3	$627K	Sell	10,591 -225	-2%	-$14.8K	0.03%	138
2021 Q2	$723K	Buy	10,816 +623	+6%	+$40.6K	0.03%	132
2021 Q1	$643K	Buy	10,193 +214	+2%	+$13.3K	0.03%	133
2020 Q4	$619K	Buy	9,979 +139	+1%	+$8.55K	0.03%	136
2020 Q3	$593K	Buy	9,840 +300	+3%	+$18.1K	0.03%	125
2020 Q2	$561K	Buy	9,540 +1,025	+12%	+$61.3K	0.03%	128
2020 Q1	$475K	Buy	8,515 +1,306	+18%	+$79.8K	0.03%	128
2019 Q4	$463K	Buy	+7,209	New	+$413K	0.02%	144
2019 Q1	–	Sell	-4,495	Closed	-$234K	–	208
2018 Q4	$234K	Buy	+4,495	New	+$242K	0.02%	172
2016 Q3	–	Sell	-3,680	Closed	-$271K	–	187
2016 Q2	$271K	Sell	3,680 -90	-2%	-$6.36K	0.02%	163
2016 Q1	$241K	Hold	3,770	–	–	0.02%	167
2015 Q4	$259K	Hold	3,770	–	–	0.02%	194
2015 Q3	$223K	Sell	3,770 -105	-3%	-$6.66K	0.02%	201
2015 Q2	$258K	Sell	3,875 -680	-15%	-$44.8K	0.02%	200
2015 Q1	$294K	Hold	4,555	–	–	0.03%	259
2014 Q4	$269K	Sell	4,555 -70	-2%	-$3.95K	0.02%	260
2014 Q3	$237K	Hold	4,625	–	–	0.02%	275
2014 Q2	$224K	Sell	4,625 -255	-5%	-$12.6K	0.02%	284
2014 Q1	$254K	Sell	4,880 -2,544	-34%	-$135K	0.03%	266
2013 Q4	$395K	Sell	7,424 -1,596	-18%	-$81.3K	0.05%	223
2013 Q3	$417K	Buy	9,020 +5	+0.1%	+$219	0.05%	218
2013 Q2	$403K	Buy	+9,015	New	+$391K	0.06%	216

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dearborn Partners's BMY Position: Q1 2026 in Review

Dearborn Partners increased its Bristol-Myers Squibb (BMY) stake by 26% in Q1 2026, buying an estimated $57.9K and bringing the position to 4,748 shares worth $288K. The position accounts for 0.02% of the portfolio, ranked #232.

Dearborn Partners first reported a position in BMY in Q2 2013 and has held it in 36 quarters since. The position peaked at $723K in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Dearborn Partners held 4,748 shares of Bristol-Myers Squibb worth $288K as of Q1 2026.
Dearborn Partners bought 993 Bristol-Myers Squibb shares in Q1 2026, an estimated $57.9K.
Bristol-Myers Squibb made up 0.02% of Dearborn Partners's portfolio in Q1 2026, its #232 holding.
Dearborn Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 36 quarters since.
Dearborn Partners's Bristol-Myers Squibb position peaked at $723K in Q2 2021.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Dearborn Partners's 13F filing for Q1 2026, filed 12 May 2026.